VIA Pharmaceuticals, Inc.
VIAP
$0.00
$0.000.00%
OTC PK
| 12/31/2010 | 09/30/2010 | 06/30/2010 | 03/31/2010 | 12/31/2009 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 788.10K | 785.00K | 995.80K | 1.67M | 1.74M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 885.40K | 1.21M | 1.39M | 2.43M | 2.81M |
| Operating Income | -885.40K | -1.21M | -1.39M | -2.43M | -2.81M |
| Income Before Tax | -2.47M | -2.12M | -2.09M | -2.92M | -4.25M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.47M | -2.12M | -2.09M | -2.92M | -4.25M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.47M | -2.12M | -2.09M | -2.92M | -4.25M |
| EBIT | -885.40K | -1.21M | -1.39M | -2.43M | -2.81M |
| EBITDA | -877.00K | -1.19M | -1.37M | -2.40M | -2.78M |
| EPS Basic | -0.12 | -0.10 | -0.10 | -0.14 | -0.21 |
| Normalized Basic EPS | -0.08 | -0.06 | -0.06 | -0.09 | -0.13 |
| EPS Diluted | -0.12 | -0.10 | -0.10 | -0.14 | -0.21 |
| Normalized Diluted EPS | -0.08 | -0.06 | -0.06 | -0.09 | -0.13 |
| Average Basic Shares Outstanding | 20.52M | 20.45M | 20.37M | 20.25M | 20.13M |
| Average Diluted Shares Outstanding | 20.52M | 20.45M | 20.37M | 20.25M | 20.13M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |